Australia's most trusted
source of pharma news
Sunday, 14 December 2025
Posted 27 October 2022 PM
Sanofi has taken its battle for the PCSK9 market to the Federal Court, targeting the patents underlying Amgen's cholesterol-lowering antibody Repatha.
Repatha was the first PCSK9 inhibitor to be listed on the PBS, back in December 2016, for homozygous familial hypercholesterolaemia. In November 2018 it had that indication extended to include heterozygous familial hypercholesterolaemia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.